$IRD

2024 Q3 Form 10-Q Financial Statement

#000114036124037068 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $3.867M $1.112M
YoY Change -67.6% -69.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.954M
YoY Change -31.94%
% of Gross Profit
Research & Development $8.982M $6.086M
YoY Change 157.07% 28.86%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0% -100.0%
% of Gross Profit
Operating Expenses $11.88M $9.440M
YoY Change 114.02% 4.16%
Operating Profit -$8.009M -$8.328M
YoY Change -225.41% 54.54%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $483.0K $563.0K
YoY Change 5.92% 31.54%
Pretax Income -$7.526M -$7.765M
YoY Change -235.0% 56.52%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.526M -$7.765M
YoY Change -235.34% 56.52%
Net Earnings / Revenue -194.62% -698.29%
Basic Earnings Per Share -$0.29 -$0.30
Diluted Earnings Per Share -$0.29 -$0.30
COMMON SHARES
Basic Shares Outstanding 26.20M 25.92M
Diluted Shares Outstanding 26.15M 25.83M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $41.41M
YoY Change 3.54%
Cash & Equivalents $36.60M $41.41M
Short-Term Investments $5.000K
Other Short-Term Assets $86.00K $87.00K
YoY Change 68.63% 93.33%
Inventory
Prepaid Expenses $343.0K $1.027M
Receivables $1.857M $1.358M
Other Receivables $0.00
Total Short-Term Assets $40.39M $44.83M
YoY Change -25.47% 3.16%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change -100.0% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $40.39M $44.83M
Total Long-Term Assets $0.00 $0.00
Total Assets $40.39M $44.83M
YoY Change -25.47% 3.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $844.0K $634.0K
YoY Change -55.34% -72.71%
Accrued Expenses $5.171M $3.490M
YoY Change 168.48% 1.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.089M $4.198M
YoY Change 55.77% -27.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.089M $4.198M
Total Long-Term Liabilities $0.00
Total Liabilities $6.089M $4.198M
YoY Change 55.77% -27.13%
SHAREHOLDERS EQUITY
Retained Earnings -$103.9M -$96.34M
YoY Change 35.47% 17.15%
Common Stock $3.000K $3.000K
YoY Change 50.0% 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $34.30M $40.64M
YoY Change
Total Liabilities & Shareholders Equity $40.39M $44.83M
YoY Change -25.47% 3.15%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$7.526M -$7.765M
YoY Change -235.34% 56.52%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Operating Activities -$7.292M
YoY Change -837.31%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.540M
YoY Change
NET CHANGE
Cash From Operating Activities -7.292M
Cash From Investing Activities 0.000
Cash From Financing Activities 1.540M
Net Change In Cash -5.752M
YoY Change -681.6%
FREE CASH FLOW
Cash From Operating Activities -$7.292M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 ocup Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
7000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
41250000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1422000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4961000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
37704000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
49906000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
985000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7106000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
46057000
CY2024Q2 ocup Contract Assets And Unbilled Receivables Current
ContractAssetsAndUnbilledReceivablesCurrent
948000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
46239000
CY2023Q1 ocup Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
2000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5791000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
804000
us-gaap Net Income Loss
NetIncomeLoss
-14871000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
432000
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001228627
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34079
dei Entity Registrant Name
EntityRegistrantName
Ocuphire Pharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3516358
dei Entity Address Address Line1
EntityAddressAddressLine1
37000 Grand River Avenue, Suite 120
dei Entity Address City Or Town
EntityAddressCityOrTown
Farmington Hills
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48335
dei City Area Code
CityAreaCode
248
dei Local Phone Number
LocalPhoneNumber
957-9024
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
OCUP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26198444
CY2023Q4 ocup Contract Assets And Unbilled Receivables Current
ContractAssetsAndUnbilledReceivablesCurrent
1407000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25827265
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25827265
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20959807
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20959807
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25175596
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25175596
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20949763
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20949763
CY2023Q1 ocup Stock Issued During Period Value Stock Exercise Of Warrants
StockIssuedDuringPeriodValueStockExerciseOfWarrants
0
CY2024Q1 ocup Stock Issued During Period Value At The Market Program And Purchase Agreement
StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
2479000
CY2024Q1 ocup Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
165000
CY2024Q1 ocup Adjustments To Additional Paid In Capital Share Repurchases For Payment Of Employee Taxes
AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes
42000
CY2024Q2 ocup Stock Issued During Period Value At The Market Program And Purchase Agreement
StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
1563000
CY2024Q2 ocup Adjustments To Additional Paid In Capital Issuance Costs Related To Common Stock Atm And Registered Direct Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
25000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
806000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7765000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
40636000
us-gaap Net Income Loss
NetIncomeLoss
-10752000
us-gaap Share Based Compensation
ShareBasedCompensation
1791000
us-gaap Share Based Compensation
ShareBasedCompensation
2226000
us-gaap Depreciation
Depreciation
0
us-gaap Depreciation
Depreciation
2000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-10000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-27000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1163000
ocup Increase Decrease In Contract Assets And Unbilled Receivables
IncreaseDecreaseInContractAssetsAndUnbilledReceivables
-459000
ocup Increase Decrease In Contract Assets And Unbilled Receivables
IncreaseDecreaseInContractAssetsAndUnbilledReceivables
-957000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-721000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1519000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1254000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1569000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1745000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13008000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2657000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4041000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
83000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
ocup Share Repurchases For Payment Of Employee Taxes
ShareRepurchasesForPaymentOfEmployeeTaxes
42000
ocup Share Repurchases For Payment Of Employee Taxes
ShareRepurchasesForPaymentOfEmployeeTaxes
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3916000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-9092000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2657000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50501000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42634000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41409000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39977000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
0
ocup Unpaid Issuance Costs
UnpaidIssuanceCosts
107000
ocup Unpaid Issuance Costs
UnpaidIssuanceCosts
9000
ocup Number Of Fda Approved Product
NumberOfFDAApprovedProduct
1
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41400000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q2 ocup Cash Equivalents Not Eligible For Fdic Coverage
CashEquivalentsNotEligibleForFDICCoverage
40900000
ocup Impairment On Investment
ImpairmentOnInvestment
0
CY2024Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2024Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
ocup Contingent Value Rights Payment Period
ContingentValueRightsPaymentPeriod
P15Y
CY2020Q4 ocup Percentage Of Cash Consideration Payment
PercentageOfCashConsiderationPayment
0.75
ocup Contingent Value Rights Ip Term
ContingentValueRightsIPTerm
P10Y
CY2024Q2 ocup Payments Due Under Cvr Agreement
PaymentsDueUnderCVRAgreement
0
CY2024Q2 ocup Number Of Milestones Accrued
NumberOfMilestonesAccrued
0
CY2021Q2 ocup Number Of Potential Milestones
NumberOfPotentialMilestones
0
CY2021Q3 ocup Number Of Potential Milestones
NumberOfPotentialMilestones
0
ocup Operating Leases Monthly Base Rent
OperatingLeasesMonthlyBaseRent
3000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
9000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
9000
us-gaap Operating Lease Cost
OperatingLeaseCost
18000
us-gaap Operating Lease Cost
OperatingLeaseCost
18000
CY2024Q2 ocup Lessee Non Cancellable Lease Liability To Be Paid One Year Or Less
LesseeNonCancellableLeaseLiabilityToBePaidOneYearOrLess
18000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1027000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
997000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
87000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
102000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1114000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1099000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q2 us-gaap Depreciation
Depreciation
1000
us-gaap Depreciation
Depreciation
2000
CY2024Q2 us-gaap Depreciation
Depreciation
0
us-gaap Depreciation
Depreciation
0
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
427000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
753000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1427000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
591000
CY2024Q2 ocup Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
1540000
CY2023Q4 ocup Accrued Research And Development Services And Supplies Current
AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
400000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
96000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
71000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3490000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1815000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
806000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1422000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1791000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2226000
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
81234
ocup Share Based Compensation Arrangement By Share Based Payment Award Services Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue
3.01
CY2023Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
4340
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
72986
CY2023Q2 ocup Share Based Compensation Arrangement By Share Based Payment Award Services Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue
6.38
ocup Share Based Compensation Arrangement By Share Based Payment Award Services Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue
3.77
CY2024Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
0
CY2023Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
28000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
245000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
275000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7300000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y9M
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q2 ocup Pretax Loss Income Tax Benefit
PretaxLossIncomeTaxBenefit
0
CY2024Q2 ocup Pretax Loss Income Tax Benefit
PretaxLossIncomeTaxBenefit
0
ocup Pretax Loss Income Tax Benefit
PretaxLossIncomeTaxBenefit
0
ocup Pretax Loss Income Tax Benefit
PretaxLossIncomeTaxBenefit
0
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
ocup-20240630_lab.xml Edgar Link unprocessable
0001140361-24-037068-index-headers.html Edgar Link pending
0001140361-24-037068-index.html Edgar Link pending
0001140361-24-037068.txt Edgar Link pending
0001140361-24-037068-xbrl.zip Edgar Link pending
ef20030049_10q.htm Edgar Link pending
ef20030049_ex10-1.htm Edgar Link pending
ef20030049_ex3-1.htm Edgar Link pending
ef20030049_ex31-1.htm Edgar Link pending
ef20030049_ex31-2.htm Edgar Link pending
ef20030049_ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ocup-20240630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ef20030049_10q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ocup-20240630_cal.xml Edgar Link unprocessable
ocup-20240630_def.xml Edgar Link unprocessable
ocup-20240630_pre.xml Edgar Link unprocessable